Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia

@article{Asnafi2006PredictionOR,
  title={Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia},
  author={V. Asnafi and M. Rubio and E. Delabesse and E. Villar and F. Davi and G. Damaj and I. Hirsch and N. Dh{\'e}din and J. Vernant and B. Varet and A. Buzyn and E. Macintyre},
  journal={Leukemia},
  year={2006},
  volume={20},
  pages={793-799}
}
  • V. Asnafi, M. Rubio, +9 authors E. Macintyre
  • Published 2006
  • Medicine, Biology
  • Leukemia
  • Chronic myeloid leukemia (CML) relapse after allogeneic stem cell transplantation (SCT) is a relatively frequent situation, which is correlated to disease status, time from diagnosis to transplant and T-cell depletion. We evaluated the potential for early minimal residual disease (MRD) BCR-ABL quantification to predict relapse of CML patients receiving allogeneic SCT. Minimal residual disease was analyzed by real-time quantitative reverse transcriptase-polymerase chain reaction (RQ-PCR) at day… CONTINUE READING

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 37 REFERENCES